These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 15213844

  • 1. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide.
    Hagemeyer CE, Tomic I, Jaminet P, Weirich U, Bassler N, Schwarz M, Runge MS, Bode C, Peter K.
    Thromb Haemost; 2004 Jul; 92(1):47-53. PubMed ID: 15213844
    [Abstract] [Full Text] [Related]

  • 2. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation.
    Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, Schmidt R, Schwarz M, Ahrens I, Katagiri Y, Pannen B, Bode C, Peter K.
    Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1206-12. PubMed ID: 17322097
    [Abstract] [Full Text] [Related]

  • 3. Identification and characterization of variants of tick anticoagulant peptide with increased inhibitory potency toward human factor Xa.
    Mao SS, Huang J, Welebob C, Neeper MP, Garsky VM, Shafer JA.
    Biochemistry; 1995 Apr 18; 34(15):5098-103. PubMed ID: 7711029
    [Abstract] [Full Text] [Related]

  • 4. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa.
    Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kübler W, Little M, Bode C.
    Circulation; 2000 Mar 14; 101(10):1158-64. PubMed ID: 10715263
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase.
    Hagemeyer CE, Tomic I, Weirich U, Graeber J, Nordt T, Runge MS, Bode C, Peter K.
    J Thromb Haemost; 2004 May 14; 2(5):797-803. PubMed ID: 15099287
    [Abstract] [Full Text] [Related]

  • 10. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa.
    Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegl PK, Vlasuk GP.
    J Biol Chem; 1990 Oct 15; 265(29):17746-52. PubMed ID: 2211658
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Structure of tick anticoagulant peptide at 1.6 A resolution complexed with bovine pancreatic trypsin inhibitor.
    St Charles R, Padmanabhan K, Arni RV, Padmanabhan KP, Tulinsky A.
    Protein Sci; 2000 Feb 15; 9(2):265-72. PubMed ID: 10716178
    [Abstract] [Full Text] [Related]

  • 13. NMR structure determination of tick anticoagulant peptide (TAP).
    Lim-Wilby MS, Hallenga K, de Maeyer M, Lasters I, Vlasuk GP, Brunck TK.
    Protein Sci; 1995 Feb 15; 4(2):178-86. PubMed ID: 7538849
    [Abstract] [Full Text] [Related]

  • 14. Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors.
    Zhu Y, Lin Y, Liu A, Shui M, Li R, Liu X, Hu W, Wang Y.
    Biochem Pharmacol; 2015 Jun 15; 95(4):253-62. PubMed ID: 25887920
    [Abstract] [Full Text] [Related]

  • 15. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
    McKenzie CR, Abendschein DR, Eisenberg PR.
    Arterioscler Thromb Vasc Biol; 1996 Oct 15; 16(10):1285-91. PubMed ID: 8857926
    [Abstract] [Full Text] [Related]

  • 16. Functional characterisation of vizottin, the first factor Xa inhibitor purified from the leech Haementeria vizottoi.
    Oliveira DG, Alvarez-Flores MP, Lopes AR, Chudzinski-Tavassi AM.
    Thromb Haemost; 2012 Sep 15; 108(3):570-8. PubMed ID: 22782262
    [Abstract] [Full Text] [Related]

  • 17. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y, Kamisato C, Morishima Y.
    Thromb Res; 2016 May 15; 141():17-21. PubMed ID: 26962981
    [Abstract] [Full Text] [Related]

  • 18. Engineering novel anticoagulant proteins by motif grafting.
    Zhu Y, Liu A, Liu X, Wang Y.
    Protein Pept Lett; 2014 May 15; 21(2):159-63. PubMed ID: 24370339
    [Abstract] [Full Text] [Related]

  • 19. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
    Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR.
    Circulation; 1995 Aug 15; 92(4):962-7. PubMed ID: 7641380
    [Abstract] [Full Text] [Related]

  • 20. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR.
    Thromb Haemost; 2003 Jan 15; 89(1):112-21. PubMed ID: 12540961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.